US 12156880
Heterocyclic RIP1 kinase inhibitors
granted A61KA61K31/55A61K31/553
Quick answer
US patent 12156880 (Heterocyclic RIP1 kinase inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K31/55, A61K31/553, A61P, A61P11/00